Urologic panels provide focused cancer testing: Sounak Gupta, M.B.B.S., Ph.D. - Insights
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS...
Colorectal panel provides detailed cancer information - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.
Focused Pharmacogenomics Panel [Test in Focus] - Insights
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for...
Breast cancer panel halves turnaround time: Wei Shen, Ph.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.
New tests launched in February - Insights
In February 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Direct Ethanol Biomarker Testing: PETH - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for...
Appropriate Use of Gastrointestinal Pathogen Panel by PCR [Utilization Spotlight] - Insights
Infectious diarrhea is a common and usually self-limited illness. While most patients with infectious causes of diarrhea will get better on their own, there are certain scenarios in which testing is indicated. The The FilmArray...
Rapid response: COVID-19, monkeypox, and whatever comes next - Insights
Mayo Clinic Laboratories' rapid response to public health threats has been honed during outbreaks of viruses like 2009’s H1N1 influenza, Zika, Ebola and, most recently, COVID-19. Before COVID-19, laboratory staff were already experts in...
An efficient, cost-effective, fungal testing alternative: Elitza Theel, Ph.D. - Insights
Elitza Theel, Ph.D., explains how Mayo Clinic Laboratories' unique Histoplasma/Blastomyces test provides cost-effective evaluation for fungal infections that cause pulmonary illness. The assay reliably detects both Histoplasma and...
Extended Spectrum Beta Lactamase Testing - Insights
Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool...